OMODA & JAECOO and Maersk team up to provide top-notch after-sales services in the UAE
Participants using tirzepatide lost 50.3 lbs. (22.8 kg) and participants on semaglutide lost 33.1 lbs. (15.0 kg). SURMOUNT-5 compared tirzepatide, a dual GIP and GLP-1 receptor agonist, to semaglutide, a mono GLP-1 receptor agonist in adults living with obesity Read More